Literature DB >> 26277624

Analysis of a FANCE Splice Isoform in Regard to DNA Repair.

Frédérick Bouffard1, Karine Plourde1, Simon Bélanger1, Geneviève Ouellette1, Yvan Labrie1, Francine Durocher2.   

Abstract

The FANC-BRCA DNA repair pathway is activated in response to interstrand crosslinks formed in DNA. A homozygous mutation in 1 of the 17 Fanconi anemia (FA) genes results in malfunctions of this pathway and development of FA syndrome. The integrity of this protein network is essential for good maintenance of DNA repair process and genome stability. Following the identification of an alternatively splice isoform of FANCE (Fanconi anemia complementation group E) significantly expressed in breast cancer individuals from high-risk non-BRCA1/2 families, we studied the impact of this FANCE splice isoform (FANCEΔ4) on DNA repair processes. We have demonstrated that FANCEΔ4 mRNA was efficiently translated into a functional protein and expressed in normal and breast cancer cell lines. Following treatment with the crosslinking agent mitomycin C, EUFA130 (FANCE-deficient) cells infected with FANCEΔ4 were blocked into G2/M phase, while cell survival was significantly reduced compared with FANCE-infected EUFA130 cells. In addition, FANCEΔ4 did not allow FANCD2 and FANCI monoubiquitination, which represents a crucial step of the FANC-BRCA functional pathway. As observed for FANCE wild-type protein, localization of FANCEΔ4 protein was confined to the nucleus following mitomycin C treatment. Although FANCEΔ4 protein showed interaction with FANCE, FANCEΔ4 did not support normal function of FANCE protein in this pathway and could have deleterious effects on FANCE protein activity. We have demonstrated that FANCEΔ4 seems to act as a regulator of FANCD2 protein expression level by promoting its degradation. This study highlights the importance of an efficient regulation of alternative splicing expression of FA genes for proper DNA repair.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DNA repair; FANCE; Fanconi anemia; alternative splicing

Mesh:

Substances:

Year:  2015        PMID: 26277624     DOI: 10.1016/j.jmb.2015.08.004

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  7 in total

1.  Distinct Metabolic Signature of Human Bladder Cancer Cells Carrying an Impaired Fanconi Anemia Tumor-Suppressor Signaling Pathway.

Authors:  Jayabal Panneerselvam; Guoxiang Xie; Raymond Che; Mingming Su; Jun Zhang; Wei Jia; Peiwen Fei
Journal:  J Proteome Res       Date:  2016-03-16       Impact factor: 4.466

2.  SFMetaDB: a comprehensive annotation of mouse RNA splicing factor RNA-Seq datasets.

Authors:  Jin Li; Ching-San Tseng; Antonio Federico; Franjo Ivankovic; Yi-Shuian Huang; Alfredo Ciccodicola; Maurice S Swanson; Peng Yu
Journal:  Database (Oxford)       Date:  2017-01-01       Impact factor: 3.451

3.  DNA methylation biomarkers for nasopharyngeal carcinoma.

Authors:  Baoai Han; Xiuping Yang; Po Zhang; Ya Zhang; Yaqin Tu; Zuhong He; Yongqin Li; Jie Yuan; Yaodong Dong; Davood K Hosseini; Tao Zhou; Haiying Sun
Journal:  PLoS One       Date:  2020-04-09       Impact factor: 3.240

Review 4.  The Interplay Between the DNA Damage Response, RNA Processing and Extracellular Vesicles.

Authors:  Xiangbing Meng; Shujie Yang; Vanessa J A Camp
Journal:  Front Oncol       Date:  2020-01-17       Impact factor: 6.244

5.  Expression and gene regulatory network of SNHG1 in hepatocellular carcinoma.

Authors:  Chaoran Zheng; Shicheng Yu
Journal:  BMC Med Genomics       Date:  2021-01-26       Impact factor: 3.063

Review 6.  Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer.

Authors:  Sarah J Taylor; Mark J Arends; Simon P Langdon
Journal:  Explor Target Antitumor Ther       Date:  2020-02-29

7.  Fanconi Anemia complementation group C protein in metabolic disorders.

Authors:  Manoj Nepal; Chi Ma; Guoxiang Xie; Wei Jia; Peiwen Fei
Journal:  Aging (Albany NY)       Date:  2018-06-21       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.